Drug Delivery, Drugs and Filler - Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Drug Delivery

Drugs

Filler

Crescita Announces Licensing Agreement for Pliaglis; in China

The Pharma Data

NOVEMBER 4, 2020

. Juyou will be responsible for the overall clinical development and regulatory filings for Pliaglis with the National Medical Products Administration (the “NMPA”, formerly the China State Food and Drug Administration). million and US$1.8 million. . Juyou Bio-Technology Co.,

Licensing

Licensing Licensing Dermatology Production

TLC Announces Full Patient Enrollment in EXCELLENCE Trial of TLC599 for Osteoarthritis PainOn-schedule completion of enrollment despite COVID-19 pandemic; unique trial design evaluates safety and efficacy of single & repeat doses

The Pharma Data

DECEMBER 27, 2020

million people misused prescription opioids in 2018, and many die every day from opioid-related drug overdoses. Current intraarticular anti-inflammatory treatments for OA have potentially toxic side effects and may lead to the destruction of cartilage filler proteins. According to the US Department of Health and Human Services, 10.3

Trials

Trials Clinical Trials Clinical Trials Containment

Crescita Announces Licensing Agreement for Pliaglis; in China

TLC Announces Full Patient Enrollment in EXCELLENCE Trial of TLC599 for Osteoarthritis PainOn-schedule completion of enrollment despite COVID-19 pandemic; unique trial design evaluates safety and efficacy of single & repeat doses

Stay Connected